Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and low-resource settings, marking a major step in fighting global HIV spread.

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines durings the world's most influential meeting on HIV research and its ...

The WHO recommends lenacapavir, an HIV prevention drug, as global funding cuts threaten efforts to combat the epidemic. Learn about its impact and challenges.

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...